Vir Biotechnology Inc reports results for the quarter ended in March - Earnings Summary

Vir Biotechnology

04/05/2023 22:11

* Vir Biotechnology Inc  VIR.OQ  reported a quarterly
adjusted
loss of $1.06​​ per share for the quarter ended in March. The
mean expectation of nine analysts for the quarter was for a loss
of 87 cents per share.
    * Revenue fell 94.9% to $62.96 million from a year ago;
analysts
expected $50.10 million. 
    * Vir Biotechnology Inc's reported EPS for the quarter was a
loss
of $1.06​.
    * The mean earnings estimate of analysts had fallen by
about 130.1% in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Vir Biotechnology Inc shares had risen by 9.1% this
quarter and
gained 0.3% so far this year.
    * The company reported a quarterly loss of $140.9 million.
    * Wall Street's median 12-month price target for Vir
Biotechnology
Inc is $43.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 09:11 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.87          -1.06          Missed
 Dec. 31 2022      -0.39          -0.76          Missed
 Sep. 30 2022      -0.21          1.30           Beat
 Jun. 30 2022      0.10           -0.58          Missed